TAP Consulting’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

TAP Consulting’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-101	Closed	-$4K	–	319
2021 Q4	$4K	Buy	+101	New	+$4.78K	﹤0.01%	479

Other funds holding IDNA

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

TAP Consulting's IDNA Position: Q1 2022 in Review

TAP Consulting sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2022, closing a stake of 101 shares — an estimated $4K sold.

TAP Consulting first reported a position in IDNA in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 86 funds tracked by Wall St. Rank hold IDNA as of Q1 2022.

TAP Consulting reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2022 after selling out during the quarter.
TAP Consulting sold 101 iShares Genomics Immunology and Healthcare ETF shares in Q1 2022, an estimated $4K.
TAP Consulting first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 1 quarter.
TAP Consulting's iShares Genomics Immunology and Healthcare ETF position peaked at $4K in Q4 2021.
86 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.